Get the Stockscreener App
6.80
2.41%
0.16
After Hours:
6.80
Puma Biotechnology Inc stock is traded at $6.80, with a volume of 424.93K.
It is up +2.41% in the last 24 hours and up +8.28% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$6.64
Open:
$6.67
24h Volume:
424.93K
Relative Volume:
0.89
Market Cap:
$342.66M
Revenue:
$230.47M
Net Income/Loss:
$30.28M
P/E Ratio:
11.15
EPS:
0.61
Net Cash Flow:
$38.86M
1W Performance:
+0.15%
1M Performance:
+8.28%
6M Performance:
+39.63%
1Y Performance:
+143.73%
1-Day Range:
$6.48
$6.83
1-Week Range:
$6.37
$7.05
52-Week Range:
$2.575
$7.285
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
6.80 | 334.60M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Re - pharmiweb.com
Puma Biotechnology sets Feb. 26 call on 2025 financial results - Stock Titan
Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Yahoo Finance
Puma Biotechnology (NASDAQ:PBYI) Shares Pass Above 200-Day Moving AverageWhat's Next? - MarketBeat
Fund Flows: Is Puma Biotechnology Inc undervalued by DCF analysisTrade Entry Report & Community Consensus Stock Picks - baoquankhu1.vn
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)February 4, 2026 - BioSpace
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule - TradingView
Puma Biotechnology (PBYI) Price Target Increased by 42.86% to 5.10 - Nasdaq
Investor Mood: How does Puma Biotechnology Inc. compare to its peersRisk Management & Risk Controlled Stock Alerts - baoquankhu1.vn
Published on: 2026-02-03 15:38:46 - baoquankhu1.vn
Universal Beteiligungs und Servicegesellschaft mbH Buys 159,200 Shares of Puma Biotechnology, Inc. $PBYI - MarketBeat
Revenue Check: Is Puma Biotechnology Inc. stock suitable for long term investing - mfd.ru
Hedge Fund Bets: Is FONAR Corporation exposed to currency risks2025 Technical Patterns & Consistent Return Strategy Ideas - baoquankhu1.vn
Surprises Report: Will Puma Biotechnology Inc benefit from rate cutsJuly 2025 Action & Verified Short-Term Plans - baoquankhu1.vn
Momentum Shift: Can CALC maintain sales growthEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand – Company AnnouncementFT.com - Financial Times
New Thai breast cancer drug helps HER2+ patients lower relapse risk - Stock Titan
Sentiment Review: How does Puma Biotechnology Inc compare to its peers2025 Institutional Moves & Safe Capital Growth Plans - baoquankhu1.vn
Zacks Research Issues Pessimistic Forecast for PBYI Earnings - MarketBeat
Ritholtz Wealth Management Raises Stake in Puma Biotechnology, Inc. $PBYI - MarketBeat
Puma Biotechnology (NASDAQ:PBYI) Share Price Crosses Above 200 Day Moving AverageWhat's Next? - MarketBeat
EPS Watch: How Puma Biotechnology Inc stock valuations compare to rivalsWeekly Stock Analysis & High Accuracy Trade Signal Alerts - Bộ Nội Vụ
Death Cross: Can Puma Biotechnology Inc stock beat analyst upgradesJuly 2025 Big Picture & High Accuracy Investment Signals - Bộ Nội Vụ
Investing in Puma Biotechnology (NASDAQ:PBYI) a year ago would have delivered you a 103% gain - Yahoo Finance
Investor Mood: What dividend safety score for Puma Biotechnology Inc. stock2025 Market Outlook & Weekly Watchlist of Top Performers - Bộ Nội Vụ
Hunt Douglas, SVP at Puma Biotechnology, sells $52,695 in PBYI By Investing.com - Investing.com UK
Will Puma Biotechnology Inc. stock keep outperforming rivalsTrade Risk Report & AI Enhanced Execution Alerts - Улправда
Puma Biotechnology (NASDAQ:PBYI) CEO Sells $105,910.56 in Stock - MarketBeat
Puma Biotechnology (NASDAQ:PBYI) Insider Douglas Hunt Sells 3,973 Shares - MarketBeat
Puma biotech CFO Nougues sells $64k in shares By Investing.com - Investing.com Australia
Auerbach Alan sells Puma Biotechnology (PBYI) shares worth $204k By Investing.com - Investing.com Australia
Hunt Douglas, SVP at Puma Biotechnology, sells $52,695 in PBYI - Investing.com
Puma biotech CFO Nougues sells $64k in shares - Investing.com
Auerbach Alan sells Puma Biotechnology (PBYI) shares worth $204k - Investing.com
Will Puma Biotechnology Inc. stock continue dividend increasesEarnings Trend Report & Reliable Price Breakout Signals - Улправда
Puma Biotechnology (NASDAQ:PBYI) Stock Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Puma Biotechnology reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Puma Biotechnology Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Up 91% in the Past Year, Is This Biotech Stock Red Hot or a Red Flag? - Yahoo Finance
Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200 Day Moving AverageHere's What Happened - MarketBeat
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference - sharewise.com
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI) - BioSpace
Puma Biotechnology Added to Nasdaq Biotechnology Index - marketscreener.com
If EPS Growth Is Important To You, Puma Biotechnology (NASDAQ:PBYI) Presents An Opportunity - Yahoo Finance
How Puma Biotechnology Inc. stock reacts to oil pricesPortfolio Value Report & Low Risk High Reward Trade Ideas - Улправда
What dividend safety score for Puma Biotechnology Inc. stockJuly 2025 Momentum & Long-Term Growth Portfolio Plans - Улправда
What analyst consensus says on Puma Biotechnology Inc. stock2025 Buyback Activity & Expert Curated Trade Setups - Улправда
History Review: How Puma Biotechnology Inc. stock reacts to oil pricesWeekly Risk Report & AI Driven Stock Reports - Улправда
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):